5 Key Takeaways
-
1
The FDA accepted Genentech’s biologics license application for investigational vamikibart, a monoclonal antibody targeting interleukin 6 for uveitic macular edema.
-
2
The phase 3 MEERKAT and SANDCAT trials enrolled 245 and 256 adults, respectively, and compared 2 vamikibart doses with sham treatment.
-
3
At week 16, both vamikibart doses met the primary endpoint in MEERKAT, whereas neither dose met it in SANDCAT under the trial’s statistical testing hierarchy.
-
4
Visual acuity and central subfield thickness improvements generally persisted through week 52, although visual acuity treatment differences narrowed in the SANDCAT 1-mg group.
-
5
Through week 52, investigators reported low rates of serious ocular adverse events and intraocular inflammation, no ocular occlusive retinal vasculitis, and no new safety signals.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







